Direkt zum Inhalt
Merck
  • Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.

Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.

Chemico-biological interactions (2014-06-03)
Enas M Ahmed, Shohda A EL-Maraghy, Zakaria A Teleb, Amira A Shaheen
ZUSAMMENFASSUNG

Previous animal studies have shown that turmeric can significantly modulate the activity of several drug metabolizing enzymes, this may dramatically affect the bioavailability of several drugs resulting in over dose or less therapeutic effects. This study was directed to evaluate the inhibitory effects of cisplatin and paclitaxel on two CYP450 enzymes namely CYP2E1 and CYP3A1/2 in hepatic microsomes isolated from normal and turmeric pretreated rats. Cisplatin and paclitaxel were added by different concentrations to hepatic microsomes isolated from untreated and turmeric (100 mg/kg/day) pretreated rats for 15 days after receiving pyrazole or dexamethasone for induction of CYP2E1 and CYP3A1/2 respectively. The kinetic potency of these drugs as CYP inhibitors was determined by analysis of Lineweaver-Burk plot. Addition of cisplatin or paclitaxel by (10, 50 and 100 μM) to hepatic microsomes from normal or turmeric pretreated rats caused a concentration dependent inhibition of CYP2E1, with an evidence of less inhibition in turmeric pretreated microsomes particularly at higher concentration. Both drugs at 100 μM displayed a mixed type of inhibition of CYP2E1 in normal or turmeric pretreated microsomes where paclitaxel was the most potent inhibitor. Cisplatin (10, 50 and 100 μM) caused a concentration dependant inhibition of CYP3A1/2 that was enhanced by turmeric pretreatment. The inhibition of CYP3A1/2 by cisplatin (100 μM) was in non-competitive manner with a smaller Ki value in turmeric pretreated microsomes. The inhibitory influence of paclitaxel (10, 50 and 100 μM) on CYP3A1/2 decreased with increasing the drug concentration and this inhibition was augmented by turmeric pretreatment. Interestingly, the inhibition of this enzyme by paclitaxel (10 μM) was switched from mixed type in normal microsomes to competitive manner in turmeric pretreated ones with a marked reduction of Ki values reflecting greater inhibitory influence of paclitaxel on CYP3A1/2 by turmeric pretreatment. In conclusion, turmeric pretreatment attenuated the inhibitory influence of cisplatin and paclitaxel on CYP2E1 activity and magnified their inhibition on CYP3A1/2, thus the use of turmeric with drugs or other medications should raise concern for drugs-herb interactions.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dexamethason, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
4-Nitrophenol, ReagentPlus®, ≥99%
Sigma-Aldrich
Dexamethason, ≥98% (HPLC), powder
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Pyrazol, 98%
Supelco
Dexamethason, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
4-Nitrophenol -Lösung, 10 mM
Sigma-Aldrich
Dexamethason, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Dexamethason, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
4-Nitrophenol, spectrophotometric grade
Sigma-Aldrich
Erythromycin-Standard -Lösung, 1 mg/mL in H2O
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexamethason, meets USP testing specifications
Supelco
4-Nitrophenol, PESTANAL®, analytical standard
USP
Erythromycin, United States Pharmacopeia (USP) Reference Standard
Supelco
Acetaminophen-verwandte Verbindung F, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Dexamethason, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethason, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethason, tested according to Ph. Eur.
Dexamethason, British Pharmacopoeia (BP) Assay Standard
Dexamethason für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Dexamethason für die Systemeignung, European Pharmacopoeia (EP) Reference Standard